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Abstract: 
Ductal Carcinoma in Situ (DCIS) is a precursor to breast cancer where abnormal cells have been 
found in the mammary duct but have not become invasive and spread into surrounding tissue. 
There has been an increase in early diagnosis of DCIS, but only around 40% of the cases ever 
progress to an invasive stage, and thus detection can lead to unnecessary surgeries. To identify 
which of these 40% progress, long noncoding RNAs were used. Through RNA sequencing of 
DCIS and invasive cells from real patient samples, BHLHE40-AS1 was discovered, a long-
noncoding RNA, to be highly expressed in invasive breast cancer and low in DCIS, suggesting 
that BHLHE40-AS1 supports breast cancer progression. We hypothesize that BHLHE40-AS1 
affects cellular protein expression and down regulates DEC1 protein expression in the cell. 
Reasons for protein loss could be through transcription, translation, and protein degradation; we 
are focusing on inhibiting transcription. To determine if BHLHE40-AS1 is altering DEC1 
mRNA abundance, we treated our cells with small interfering RNA (siRNA). A qPCR was 
conducted to observe the knockdown of the expression of BHLHE40-AS1 and of DEC1. The 
siRNA was targeted against BHLHE40-AS1, and when we observed knockdown of BHLHE40-
AS1 we also got knockdown of DEC1 mRNA. To determine the half-life of DEC1 we used 
Actinomycin D, which is known to inhibit transcription and measure mRNA abundance over 
time. When measuring the stability of DEC1 RNA with siRNA’s, the change in rate between the 
siRNA’s and the control is small leading to the conclusion that the effect on DEC1 is not due to 
transcript degradation, but may be due to a problem with transcription. To validate this 
hypothesis, we will next perform a nuclear run-on assay.  In conclusion, we have identified a 
long noncoding RNA that may support breast cancer progression, through interaction with 
DEC1. After validating our observations, we will test BHLHE40-AS1 affect on progression an in 
vivo mouse model 
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Introduction: 
 Breast cancer is the most common cause of death in women around the world. Risks 
factors for Breast cancer can include: age, genetic mutations, and family history. Breast cancer is 
characterized by different stages of the disease’s progression, as well as by whether the cancer is 
invasive or non-invasive (Key, 2001). We are working with stage zero breast cancer or also 
known as Ductal Carcinoma in Situ (DCIS). 
 Ductal Carcinoma in Situ (DCIS) is a precursor to breast cancer where abnormal cells 
have been found in the mammary duct but have not become metastatic (Figure.1) (Van Cleef, et 
al, 2014). Metastasis is a process in which tumor cells can spread and invade surrounding tissues. 
This process is responsible for 90% of cancer related deaths, however mechanisms by which 
metastasis occurs are not known  (Wang, 2010). Once the cells become invasive and escape the 
duct, we have a cancerous, potentially metastatic and life threatening disease, breast cancer. The 
risk in developing DCIS starts at the age of 40 and reaches a plateau after age of 60, most 
commonly among African American, Asian, and Hispanic Women (Van Cleef, et al, 2014). 
DCIS in most cases has no symptoms, and could be diagnosed through a mammography, or a 
biopsy (Mayo Clinic, 2014). DCIS usually cannot be detected by a clinical examination (Van 
Cleef, et al, 2014).  
 There has been an increase in early diagnosis of DCIS over the past 30 years, but only 
around 30% of the cases ever progress to an invasive stage, and thus tens of thousands of women 
each year undergo unnecessary surgery and radiation therapy (Morris E, et al, 2015). In our lab, 
we are studying to determine the 30% of these cases that do in fact progress to an invasive stage. 
To study these cases, we investigated the role of long-noncoding RNA in DCIS detection.  
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 Long noncoding RNAs (lncRNA) were thought to play no vital roles when discovered 
that they are incapable of coding for proteins (Poting, et al, 2009). However, it was found these 
long noncoding RNAs could directly regulate the stability of mRNA, and a play a role in a 
number of other functions such as: regulating biological processes, gene expression, genomic 
imprinting, and playing important roles in tissue homeostasis conditions (Wang, Shan, Yao, 
2016). In the lab, we have found evidence of, and are studying, the long noncoding RNAs that 
influence DCIS progression. In collaboration with Dr. Behbod at the University of Kansas 
Medical center, we took biopsies from patients with pre-invasive and invasive cells. These 
samples were subjected to RNA sequencing from where we identified long non-coding RNAs 
that were expressed on DCIS and invasive cells. We discovered a long noncoding RNA, 
BHLHE40-AS1, being expressed on the invasive cells (Figure 2). 
 We hypothesize that BHLHE40-AS1 affects cellular protein expression and down 
regulates DEC1 protein expression in the cell. To test our hypothesis, we used GapmeRs (or 
Antisense Oligonucleotides (ASOs)). ASOs function in the cytoplasm and knockdown the 
expression of RNA by attaching to a link and being cleaved by RNAse H leading to the down 
regulation of protein (Walder, 1988). The decrease in DEC1 protein could be through the process 
of transcription, translation, and/or protein degradation; the lab is focused on DEC1 protein loss 
in relation to the process of transcription.  
 To test our hypothesis we conducted a series of experiments: western blotting, and qPCR. 
The process of identifying and separating proteins is known as western blotting. Western blotting 
consists of three steps: A separation by size, transfer to a solid support, and marking target 
protein using a proper primary and secondary antibody to visualize (Mahmood, Yang, 2012). We 
used this technique to observe how much DEC1 protein is in each well when the ASOs/siRNA 
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are present. We then used this information to design an experiment to test the transcript stability 
of BHLHE40-AS1. To do this, we conducted qPCR’s. PCR stands for Polymerase Chain 
Reaction, a technique that allows rapid amplification of a specific segment of DNA. On the other 
hand, quantitative PCR (qPCR) provides information, that indicates how much specific DNA or 
gene is present in the sample. 
 The PCR process contains three steps: Denaturation, annealing, and extension. The 
reaction solution is first heated above the melting point, allowing the strands to separate, 
denaturation. In this step, the DNA is denaturing, unwinding, and breaking the hydrogen bonds 
that hold together the two strands of the DNA molecule, leaving us with a single stranded DNA. 
The temperature is then lowered, allowing the specific primers to bind to the target DNA. This 
provides a starting place for the DNA polymerase to bind and replicate the target DNA. Lastly, 
the temperature is raised again, which allows the DNA polymerase to extend the primers, adding 
nucleotides to the developing strand (Garibyan, 2013). For our experiment, conducting a qPCR is 
very important because we want to know how much DNA/RNA is present at a certain time point. 
This allows for the identification of whether the ASO’s or the siRNA’s are knocking down the 
expression of BHLHE40-AS1, leading to a loss of protein.  
 
Materials and Methods: 
Development of western blot 
Using this technique, we can separate proteins based on mass (kDA), and we do this 
through gel electrophoresis. The samples are loaded; 10ul ladder, 10ul control, 10ul ASO 2, 10ul 
ASO 3, and 30ul ASO 4. The 12% tri-glycine gel runs at 100 volts. These results are then 
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transferred to a membrane (PVDF), in transfer buffer and are run in the cold room at 100 volts 
for one hour. This produces a band for each protein present. An antibody is used to specifically 
detect its antigen. An antibody has a specific function, and its specificity of the antibody-antigen 
interaction enables a target protein to be identified (either labeled with an enzyme or fluorescent 
dye). In our case we used the primary antibody for rabbit, therefore the secondary antibody was 
anti-rabbit to detect the target antigen (Anti-Rabbit, ThermoFisher). We used a primary antibody 
that specifically binds to the protein, and was left in the cold room overnight on rotator. The 
membrane was then washed three times with tri-buffered saline (TBST) the following day. The 
main purpose of using TBST is to prevent non-specific binding of the antibody. After the three 
washes, the secondary antibody (rabbit), 1.5ul was added, and placed on rotator for one hour. 
The membrane was then rinsed an additional three times with TBST. To develop our western 
blot, we added 1 mL of each developing reagent (developing reagent must not be mix), and 
scanned it using the STORM machine. 
Transfection 
The siRNA’s plus RNAimax and serum free media were added to the plates and collected 
the cells to observe the knockdown expression. We added 10 microliters of the siRNA and 7.5 
microliters of the RNAimax. RNAimax is a lipid that forms a bubble around the siRNA and can 
incorporate with the cell membrane to deliver its target. 1mL serum-free media was added to the 
cells and was left to complex for 10 minutes. Serum free media is used because serum has 
growth factors to allow the cell to grow; proteins in the serum would interfere with the bubble 
formation, and possible contamination with RNAses is avoided (Factors Influencing 
Transfection, ThermoFisher). At 10 minutes start incubating trypsin on cells, by removing the 
media and rinsing with 5mL of Phosphate-buffered saline (PBS). PBS was removed, and 1mL of 
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trypsin was added. PBS washing is needed to remove serum of media to allow trypsin to detach 
the cells from the plate; trypsin is a protease that cuts the proteins between the cell and the ECM 
(PRSS1 gene, 2012). The cells were incubated and checked after two minutes. The cells were 
collected and 4mLs of 10A media was added. The total 5mLs was added to a 15mL conical tube. 
1mL of cells from the 15mL conical tube was added into three wells in a six well plate, for three 
plates. 10uL of the cells from the 15mL conical tube were counted to determine the amount of 
cell/mL 
Math: 
 100,00 cell/mL (1/35 x 10^4 cells) = .2857= ~. 29 .71 x 10= 7.1mL media and 2.9mL 
cells.  
 We collected the cell plate after 72hrs and performed RNA extraction and then a qPCR. 
This transfection was conducted for the siRNA control, 12, and 15. This method could also be 
performed for the ASO’s.  
Actinomycin D 
 The transfected cells were removed from the incubator (37˚ Celsius) and placed under the 
hood. An aspirator was used to remove the media that was already inside on top of the cells (Do 
not remove media until master mix is made to avoid cells being dried). 2mL of Actinomycin D 
was added to each plate. We observed the plated cells for a total of 5 hours (0,1,2,3,5). Each 
plate had its RNA extracted using the complete RNA kit. 
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Math:  
1mM actinomycin D = 1.2 ug/ul, we want 5ug/mL in 2 mL. (1.2ug/mL) x V1 = 5ug/mL x 2mL.  
(1.2ug/mL) x V2 = 5ug/mL x 8mL. V1= 33.3ul. 45ugh/mL ÷ 1.2ug/mL = 37.5uL. 5ug x 20mL = 
100uL/1.2ug = 83.3 uL 
E.Z.N.A Total RNA Kit I  
The cells were disrupted using TRK lysis buffer. 700ul of TRK lysis buffer plus 20uL B-
me per mL of lysis buffer was added into each well. The cells were then scrapped and collected 
in a 1.5 mL centrifuge tube. One volume of ethanol (700uL) was added. Ethanol is added to 
provide appropriate binding conditions. A HiBind Mini Column is inserted into a 2 mL 
collection tube. 700uL of the sample is transferred into the HiBind RNA Mini Column, and 
centrifuge at 10,000-x g for 1 minute. The filtrate was discarded and this step was repeated until 
the entire sample had been transferred. 500uL of RNA Wash buffer I was added to the HiBind 
Mini Column, and centrifuged at 10,000 x g for 30 seconds. The filtrate was discarded. 500uL of 
RNA Wash Buffer II was added to HiBind Mini Column and centrifuged at 10,000-x g for one 
minute, discarding filtrate and repeating this step one more time. The RNA Wash Buffer II 
contains 100% ethanol. This step is crucial because it forces the precipitation of nucleic acid out 
of solution. The HiBind Mini Column is centrifuged at maximum speed for two minutes to 
completely dry. It is important to dry the HiBind Mini Column because residual ethanol may 
interfere with downstream applications. The HiBind Mini Column is transferred to a 1.5 mL 
centrifuge tube and treated with 40uL of DEPC water, and centrifuged at maximum speed for 
two minutes.  
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cDNA Reverse Transcriptase  
The RNA samples are spec using a spectrometer (used for measuring the amount of RNA 
present). After the amount of RNA to be reverse is determined, it is added to a PCR tube. The 
RNA sample is diluted to 10uL with RNAse free water. A master mix is created using: 10x RT 
buffer, 25x dNTP, 10x RT random primers, multiscribe RT (added last), and RNAse free water. 
10uL of the master mix is added to the 10uL of RNA and placed in a thermocycler. The resulting 
complementary DNA (cDNA) is ready for dilution and to be used in qPCR. cDNA is the product 
of the synthesis of DNA from an RNA template. DNA is a lot more stable than RNA, and PCR 
amplification only works on DNA.  
Quantitative Polymerase Chain Reaction (qPCR). 
 The cDNA samples are diluted with 180uL of RNAse free water. A master mix was 
created for DEC1, 18s, and ABI. 5uL of the cDNA samples were plated in a 384 well plate, 
following 5uL of the taqmam. The plate is placed into the qPCR machine and ran for 1 hour and 
35 minutes. Once this is done, we obtain our results.  
 
Results: 
 Our hypothesis was that BHLHE40-AS1 affects cellular protein expression and down 
regulates DEC1 protein expression in the cell. To test this hypothesis, cells were treated with 
small interfering RNA (siRNA), ASOs, and a qPCR was conducted to observe the knockdown of 
both BHLHE40-AS1 and of DEC1 expression. The siRNA was targeted against BHLHE40-AS1, 
and when we observe knockdown of BHLHE40-AS1 we also get knockdown of DEC1 mRNA.  
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Loss of DEC1 expression 
 We performed a western blot to observe if there was a change in DEC1 protein. 
However, when we scanned our membrane using the STORM machine, we did not obtain the 
results that we were hoping for; the bands did not match our predictions of change in DEC1 
protein. The membrane containing the protein was washed three times with tri-buffered saline 
(TBST) and the secondary antibody was added once more. After re-adding the secondary 
antibody for a second time, we still did not get the results that were expected. Therefore, we re-
added the primary antibody to the membrane and left it overnight. We re-developed, and 
observed that when the ASOs are in the cell, we also see a loss of DEC1 protein (Figure.3). We 
do see a change in DEC1 protein, suggesting that the mRNA change is sufficient to reduce 
protein accumulation. 
ASOs knockdown expression of BHLHE40-AS1 
 After the cells were transfected with the ASOS, a qPCR was conducted to observe the 
knockdown of the expression of the long noncoding RNA BHLHE40-AS1. When the ASOs are 
added into the cell, they knockdown the expression of BHLHE40-AS1 (Figure.4) 
Measuring the stability of BHLHE40-AS1 
 To measure the half-life of BHLHE40-AS1, and DEC1 and compare it to hour zero, we 
inhibited transcription using Actinomycin D. Actinomycin D prevents RNA Polymerase 
progression by different concentrations; there are three classes of gene transcription, each with a 
different concentration. By hour 5, we lost 60% of our mRNA for DEC1 under control conditions 
(Figure.5). This indicates that DEC1 has a short mRNA half-life.  
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Knock down of DEC1 using Actinomycin D 
 We repeated the experiment using ASO 2 and ASO 3 to test the stability of the mRNA. 
With ASO 2 we lost transcript at a much faster rate, suggesting that BHLHE40-AS1 helps with 
the production and/or stability of the mRNA of DEC1 (Figure.6). However with ASO 3, we saw 
something different; we saw that relative to the control, there was more mRNA stating that it is 
more stable (Figure.7). These results were then compared to our previous experiment which were 
done using siRNAs. 
siRNA Knockdown of BHLHE40-AS1 
 siRNAs were added to observe the knockdown of BHLHE40-AS1. We noticed that we 
have knocked down expression of the RNA, meaning that they do work (Figure.8). siRNA 
mediated Knockdown of BHLHE40-AS1 attenuates DEC1 expression. Because we knocked 
down expressions of the RNA it means that we got rid of DEC1 expression (when we have 
knock down of BHLHE4-AS1, we also have knockdown of DEC1 expression) (Figure.9).  
 To summarize our results, when we have knockdown of BHLHE40-AS1 we also see a 
lost of DEC1 protein, leading to our next hypothesis is the effect on DEC1 due to transcript 
degradation?  
 
Discussion/Conclussion: 
We have identified a long noncoding RNA that may support breast cancer progression, 
through interaction with DEC1. Knockdown of BHLHE40-AS1 throgh ASOs and siRNAs, 
results in loss of DEC1 protein. If BHLHE40-AS1 is indeed linked to breast cancer progression, 
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it can be utilized to create better diagnostic tests to improve patient treatment options and 
outcomes.  
To discuss our next hypothesis; is the effect on DEC1 due to transcript stability 
(Figure.10)? And is the change in (Figutr.9) enough to result in (Figure.8)? We measured the 
effect on DEC1, and determined that the transcript degradation could be because we started with 
less RNA. In comparison to the control, the change in loss of transcript between the blue bar and 
the green bar is very small. We are interpreting that the transcript is degrading at the same rate of 
the control; this together means that when we conduct our experiment we could be starting with 
less RNA.  
To further validate our hypothesis, we will next perform a nuclear run-on assay (NOA). 
Taking our results from our first hypothesis into consideration, what can we learn from the 
nuclear run-on-assay?  
o If we are starting off with less RNA, could we see why? What is going on that is 
resulting in the loss of RNA? 
o Nuclear run-on-assay measures genes that are actively being transcribed 
In order to perform a nuclear run on assay we will need to optimize some conditions. The 
condition that needs to be optimized is: finding a time point that would work best at knocking 
down the expression of DEC1. We designed an experiment using 24, 48, 72 hour time points, but 
unfortunately there were some technical errors.  
Our hypothesis for the nuclear run on assay is, that we may be starting with the less RNA 
in the first place, which may mean, that something is acting to get rid of the transcript. We 
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determined that compared to the control, we are losing transcript for siRNA 15 at a similar rate. 
With the nuclear run on assay it will tell us if something is going on at the beginning of the 
process, however it will not tell us why. If we are able to see the abundance of the RNA at the 
beginning of transcription, then we can confidently say that we are losing the RNA.  
During transcription, if we have knockdown of cells and we see that they are all stuck in 
mitosis, the cell is not transcribing anything. If the knockdown is producing other effects like on 
cell cycles, we can see an effect on transcription as well. In order to perform the nuclear run on 
assay, we would need at least 6 million cells, and primers that should be 10-22 nucleotides in 
length, have GC content of 40-60%, and produce short (50-120 base pair) amplicon (Roberts, et 
al, 2015). However, we do not want to do a nuclear run on assay because it is a very technical, 
challenging experiment to do. Nuclear run on assay uses phosphate 32, which is radioactive; 
radiation could isolate RNA, but in order to use radiation we have to be certified. Instead we are 
using a click-it kit because it offers, an easier, faster, alternative way. We essentially want to do 
the NOA but through the other kit. The click-it kit captures the newly made RNA; the newly 
made is composed of introns and exons. After validating our observations, we will test 
BHLHE40-AS1 effect on progression an in vivo mouse model.  
Our hopes are to be able to apply these findings to humans. By applying these findings to 
humans we could avoid: unnecessary treatments, therapies, and target the breast cancer cases that 
will progress to an aggressive, invasive, stage.  
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Figures: 
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Here we can see how the normal cells are aligned to the 
mammary duct with no abnormal growth, compared to DCIS. In the 
DCIS we can see that there is abnormal growth but it is still contained 
within the mammary duct. An invasive stage is where the cells have 
grown outside of them. 
Adapted from: Range of Ductal Carcinoma in situ (DCIS). (n.d.). Retrieved March 16, 2015, from 
http://www.breastcancer.org/pictures/types/dcis/dcis_range 
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Figure 2:  
A) Shows a patient mammogram where we can see both a DCIS lesion (stage 0) and an 
invasive lesion (breast cancer).  
B) Is an H&E stain (the cancer cells are purple, the duct is pink) of a DCIS lesion (cancer cells 
remain inside the duct) 
C) Is an H&E stain of an invasive lesion where the cancer cells are spread throughout the tissue.  
These samples were subjected to RNA sequencing from where we identified long noncoding 
RNAs that were DCIS and invasive. This is represented in the heat map. 
 
DCIS Invasive 
 
Fariba Behbod et al. University of Kansas Medical Center 
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Figure 3: Loss of DEC1 protein. Samples were treated with 
ASOs (control, 2, and, 3). Samples were run on a 12% tris-
glycine gel, at 100 volts. GAPDH was used as a loading control.  
 
 
 
 
 
 
 
 
 
 
Figure 4: Knockdown of BHLHE40-AS1 expression. A qPCR was 
conducted using the ASOs on the long noncoding RNA BHLHE40-
AS1 at 72 hours.  
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Figure 6:  Knockdown of DEC1. Using Actinomycin D to inhibit 
transcription, a qPCR was conducted to observe the RNA expression 
of DEC1. With ASO 2 the transcript was lost at a much faster rate.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5:  Knockdown of DEC1 under control conditions. Using 
Actinomycin D to inhibit transcription, a qPCR was conducted to 
observe the RNA expression of DEC1. By hour 5, we lost 60% of 
mRNA.  
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Figure 7:  Knocking down of ASO’s of DEC1. Using Actinomycin D 
to inhibit transcription, a qPCR was conducted to observe the RNA 
expression of DEC1. With ASO 3 the transcript was loss at a much 
slower rate than the control. 
 
 
 
 
 
 
 
 
 
 
Figure 8:  siRNA knockdowns of BHLHE40-AS1. Using 
Actinomycin D to inhibit transcription, a qPCR was conducted to 
observe the RNA expression of BHLHE40-AS1.  
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Figure 9:  a siRNA knockdown of BHLHE40-AS1 attenuates DEC1 
expression. Using Actinomycin D to inhibit transcription, a qPCR 
was conducted to observe the RNA expression of BHLHE40-AS1 
affect on DEC1.  
 
 
 
 
 
 
 
 
 
 
Figure 10:  The effect on DEC1 due to transcript stability. Using 
Actinomycin D to inhibit transcription, a qPCR was conducted to 
observe the RNA expression of BHLHE40-AS1 affect on DEC1 mRNA. 
Relative to the control, the loss of transcript is very small.   
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